Glenn J. Lesser, M.D.Wake Forest Baptist Health

Doctor Rating

4.7 out of 5

145 Ratings

Glenn J. Lesser, M.D.


Clinical Interests

Brain Tumors, Cancer Pain Control, Cancer Symptom Management, Neuro-oncology

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-713-5440

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.A., Duke University, 1983
  • M.D., Penn State University College of Medicine, 1987
  • Residency, Internal Medicine, North Carolina Baptist Hospita, 1991
  • Fellowship, Johns Hopkins University Schoo, 1994
  • Internship, Internal Medicine, North Carolina Baptist Hospita, 1998


  • Am Coll of Physicians Fellow
  • Am Medical Assn
  • Am Soc of Clinical Oncology
  • North Carolina Medical Assn
  • Society of Neuro-Oncology
  • Southern Assn For Oncology
  • Southern Medical Association

NPI Number

  • 1205810660
Glenn J. Lesser, M.D.

Doctor Rating

4.7 out of 5

145 Ratings

Glenn J. Lesser, M.D.

Professor, Hematology & Oncology
Brain Tumor Center of Excellence
Comprehensive Cancer Center

Research Interests

alternative medicine, cancer/oncogenesis, drugs/therapeutic agents pharm, molecular biology/molecular me, rare diseases, vaccines

Contact Information

Academic: 336-716-9527 | Department: 336-713-5440

Media Medical Expert »

Recent Publications

Lewis JA, Petty WJ, Harmon M, Peacock JE, Valente K, Owen J, Pirmohamed M, Lesser GJ. Hemolytic anemia in two patients with glioblastoma multiforme: a possible interaction between vorinostat and dapsone. J Oncol Pharm Pract. 2015;21(3):220-223.

Fisher BJ, Hu C, Macdonald DR, Lesser GJ, Coons SW, Brachman DG, Ryu S, Werner-Wasik M, Bahary JP, Liu J, Chakravarti A, Mehta M. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424. Int J Radiat Oncol Biol Phys. 2015;91(3):497-504.

Mirlohi S, Duncan SE, Harmon M, Case D, Lesser G, Dietrich AM. Analysis of salivary fluid and chemosensory functions in patients treated for primary malignant brain tumors. Clin Oral Investig. 2015;19(1):127-137.

Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015;121(2):297-302.

Lucas JT Jr, Huang AJ, Mott RT, Lesser GJ, Tatter SB, Chan MD. Anaplastic ganglioglioma: a report of three cases and review of the literature. J Neurooncol. 2015;123(1):171-177.

Page BR, Shaw EG, Lu L, Bryant D, Grisell D, Lesser GJ, Monitto DC, Naughton MJ, Rapp SR, Savona SR, Shah S, Case D, Chan MD. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro Oncol. 2015;17(10):1393-1401.

Lawrence JA, Griffin L, Balcueva EP, Groteluschen DL, Samuel TA, Lesser GJ, Naughton MJ, Case LD, Shaw EG, Rapp SR. A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv. 2015;():.

Armstrong TS, Wen PY, Reardon DA, Phuphanich S, Aiken R, Landolfi JC, Curry WT, Zhu JJ, Glantz MJ, Peereboom DM, Markert J, LaRocca RV, O'Rourke D, Fink KL, Kim LJ, Gruber ML, Lesser GJ, Pan E, Kesari S, Yu J. Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107 [abstract]. J Clin Oncol. 2015;33(15 Suppl):2036.

Greven KM, Case LD, Nycum LR, Zekan PJ, Hurd DD, Balcueva EP, Mills GM, Zon R, Flynn PJ, Biggs D, Shaw EG, Lesser G, Naughton MJ. Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106. J Community Support Oncol. 2015;13(3):87-94.

Holdhoff M, Ye XB, Nabors LB, Desai AS, Mikkelsen T, Lesser G, Read WL, Lieberman FS, Supko J, Fisher JD, Desideri S, Grossman SA, Schiff D. Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: a phase I Adult Brain Tumor Consortium study [abstract]. J Clin Oncol. 2015;33(15 Suppl):2033.

Laack NN, Galanis E, Anderson SK, Leinweber C, Buckner JC, Giannini C, Geoffroy FJ, Johnson DR, Lesser GJ, Jaeckle KA, Sarkaria JN. Randomized, placebo-controlled, phase II study of dasatinib with standard chemo-radiotherapy for newly diagnosed glioblastoma (GBM), NCCTG N0877 (Alliance) [abstract]. J Clin Oncol. 2015;33(15 Suppl):2013.

Qin R, Tan AD, Sloan JA, Johnson DR, Lesser GJ, Anderson SK, Laack NN. Quality of life analysis of NCCTG N0877 (Alliance): phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM)[abstract]. J Clin Oncol. 2015;33(15 Suppl):e17715.

Gifford A, Lawrence J, Case D, Rapp S, Baker L, Craft S, Groteluschen DL, Klepin H, Lesser G, Naughton MJ, Sachs B, Samuel TA, Sink K, Williamson, J, Shaw EG. Mild cognitive impairment (MCI) in chemotherapy-treated breast cancer survivors [abstract]. J Clin Oncol. 2015;33(15 Suppl):9560.

Strowd RE, Russell G, Harmon M, Carter AF, Chan MD, Tatter SB, Laxton AW, High K, Lesser G. Immunologic response to high-dose influenza vaccination in patients with primary central nervous system malignancy (PCNSM) [abstract]. J Clin Oncol. 2015;33(15 Suppl):e20669.

Weaver KE, Urbanic JJ, Case D, Kaplan SG, Lesser GJ, Zbikowski S, Bryant D, Dakhil SR, Wilson C, Shaw EG, Danhauer S. Preliminary efficacy of an enhanced quitline smoking cessation intervention for cancer patients [abstract]. J Clin Oncol. 2015;33(15 Suppl):e20671.

Urbanic JJ, Case D, Baez-Diaz L, Brown DR, Strasser J, Enevold G, Naughton M, Weaver KE, Baglan K, Bryant D, Langefeld C, Lad TE, Lee L, Rine G, Curtis AE, Koprowski CD, Tomlinson WV, Lesser GJ, Shaw EG, Hu JJ,. A prospective evaluation of radiotherapy (RT) related skin reactions in a multi-racial/ethnic population of women with newly diagnosed breast cancer (BC) [abstract]. J Clin Oncol. 2015;33(15 Suppl):6593.

Renfrow JJ, Mitchell JW, Goodman M, Mellen LA, Wilson JA, Mott RT, Lesser GJ. Relapsing intracranial plasma cell granuloma: a case report. Oncol Lett. 2014;7(2):531-533.

Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol. 2014;37(2):177-181.

Strowd RE, Swett K, Harmon M, Carter AF, Pop-Vicas A, Chan M, Tatter SB, Ellis T [deceased], Blevins M, High K, Lesser GJ. Influenza vaccine immunogenicity in patients with primary central nervous system malignancy. Neuro Oncol. 2014;16(12):1639-1644.

Leyrer CM, Chan MD, Peiffer AM, Horne E, Harmon M, Carter AF, Hinson WH, Mirlohi S, Duncan SE, Dietrich AM, Lesser GJ. Taste and smell disturbances after brain irradiation: a dose-volume histogram analysis of a prospective observational study. Pract Radiat Oncol. 2014;4(2):130-135.

Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol. 2014;119(2):429-435.

Huang AJ, Huang KE, Page BR, Ayala-Peacock DN, Lucas JT Jr, Lesser GJ, Laxton AW, Tatter SB, Chan MD. Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery. J Neurooncol. 2014;120(1):163-169.

Shaw E, McKee N, Case D, Lawrence J, Lesser G, Naughton M, Peiffer A, Loghin M, Giguere J, Stieber V, Rapp S. Incidence of mild cognitive impairment in irradiated brain tumor survivors [abstract]. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S162-S163.

Urbanic JJ, Case D, Lesser G, Enevold G, Naughton M, Danhauer S, Rapp S, Vitolins M, Johnson S, McCollough M, Duncan D, Papagikos M, Shaw EG. L-arginine - based nutritional supplement did not improve erectile function or quality of life in prostate cancer survivors previously treated with radiation therapy: results of CCOP research base protocol 98110-A randomized phase 2 dose. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S86-S87.

Holmes JA, Paulsson A, Peiffer AM, Miller LD, Xu J, Hinson WH, Lesser GJ, Tatter SB, Debinski W, Chan MD. Genomic predictors of infield and marginal failure for glioblastoma treated with concurrent radiation therapy and temozolomide: a step towards personalized radiation fields? [abstract]. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S291-S292.

Lesser G, Harmon M, Khan I, Whitlow C, Brown W. Cellular microparticles as blood-borne endothelial biomarkers in patients with malignant gliomas [abstract]. Neuro Oncol. 2014;16(Suppl 5):v27.

Strowd R, Russell G, Harmon M, Carter A, Chan M, Tatter S, Laxton A, High K, Lesser G. A pilot study of high-dose influenza vaccine immunogenicity in patients with primary central nervous system malignancy [abstract]. Neuro Oncol. 2014;16(Suppl 5):v207.

Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W, Zhu JJ, Glantz M, Peereboom D, Markert J, Larocca R, O'Rourke D, Fink K, Kim L, Gruber M, Lesser G, Pan E, Kesari S, Yu J. A randomized double blind placebo-controlled phase 2 trial of dendritic cell (DC) vaccine ICT-107 following standard treatment in newly diagnosed patients with GBM [abstract]. Neuro Oncol. 2014;16(Suppl 5):v22.

Vincent A, Lesser G, Brown D, Vern-Gross T, Metheny-Barlow L, Lawrence J, Chan M. Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature. J Breast Cancer. 2013;16(1):122-126.

Lesser GJ, Case D, Stark N, Williford S, Giguere J, Garino LA, Naughton MJ, Vitolins MZ, Lively MO, Shaw EG. A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer. J Support Oncol. 2013;11(1):31-42.

Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013;15(7):930-935.

Kota G, Gupta P, Lesser GJ, Wilson JA, Mintz A. Somatostatin receptor molecular imaging for metastatic intracranial hemangiopericytoma. Clin Nucl Med. 2013;38(12):984-987.

Somasundaram A, Lesser GJ, Mott RT, Hsu W. Malignant transformation of an intramedullary epidermoid cyst in the thoracic region of the spinal cord: case report. J Neurosurg Spine. 2013;19(5):591-594.

Strowd RE, Blackwood R, Brown M, Harmon M, Lovato J, Yalcinkaya T, Lesser G. Impact of temozolomide on gonadal function in patients with primary malignant brain tumors. J Oncol Pharm Pract. 2013;19(4):321-327.

Renfrow JJ, Lesser GJ. Molecular subtyping of brain metastases and implications for therapy. Curr Treat Options Oncol. 2013;14(4):514-527.

Morrell RM, Tooze JA, Harmon MS, Carter AF, DeTroye AT, Lesser GJ. An automated system for detecting nonadherence in laboratory testing and monitoring for myelosuppression in patients receiving self-administered oral chemotherapy. J Oncol Pract. 2013;9(5):E268-E271.

Vitolins MZ, Griffin L, Tomlinson WV, Vuky J, Adams PT, Moose D, Frizzell B, Lesser GJ, Naughton M, Radford JE Jr, Shaw EG. Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer. J Clin Oncol. 2013;31(32):4092-4098.

Norden A, Schiff D, Ahluwalia M, Lesser G, Nayak L, Lee E, Muzikansky A, Dietrich J, Smith K, Gaffey S, McCluskey C, Ligon K, Reardon D, Wen P. Phase II trial of triple receptor tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas [abstract]. Neuro Oncol. 2013;15(Suppl 3):123-124.

Norden A, Hammond S, Drappatz J, Phuphanich S, Reardon D, Wong E, Plotkin S, Lesser G, Raizer J, Batchelor T, Lee E, Kaley T, Muzikansky A, Doherty L, LaFrankie D, Ruland S, Smith K, Gerard M, McCluskey C, Wen P. Phase II study of monthly pasireotide lar (Som230C) for recurrent or progressive meningioma: final results [abstract]. Neuro Oncol. 2013;15(Suppl 3):123.

Shaw EG, Case D, Bryant D, Grisell D, Lesser G, Monitto DC, Naughton MJ, Rapp SR, Sovano SR, Shah S, Chan MD. Phase II double-blind placebo-controlled study of armodafinil for brain radiation induced fatigue [abstract]. J Clin Oncol. 2013;31(15 Suppl):9505.

Urbanic JJ, Case D, Naughton MJ, Hu JJ, Enevold G, Beech B, Weaver KE, Danhauer S, Rapp SR, Sheidler V, Vitolins M, Lesser G, Shaw EG. Minority accrual on a prospective study targeting a diverse US breast cancer population: an analysis of Wake Forest CCOP research base protocol 97609 [abstract]. J Clin Oncol. 2013;31(15 Suppl):6564.

Monjazeb AM, Ayala D, Jensen C, Case LD, Bourland JD, Ellis TL, McMullen KP, Chan MD, Tatter SB, Lesser GJ, Shaw EG. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012;82(2):743-748.

Ruiz J, Case D, Enevold G, Rosdhal R, Tatter SB, Ellis TL, McQuellon RP, McMullen KP, Stieber VW, Shaw EG, Lesser GJ. A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. J Neurooncol. 2012;106(3):611-617.

Geer CP, Simonds J, Anvery A, Chen MY, Burdette JH, Zapadka ME, Ellis TL, Tatter SB, Lesser GJ, Chan MD, McMullen KP, Johnson AJ. Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study. AJNR Am J Neuroradiol. 2012;33(3):556-562.

Renfrow JJ, DeTroye A, Chan M, Tatter S, Ellis T, McMullen K, Johnson A, Mott R, Lesser GJ. Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report. J Neurooncol. 2012;107(3):659-663.

Garcia-Espinosa MA, Lesser GJ, Debinski W, Tallant EA, Gallagher PE. Angiotensin-(1-7), a peptide hormone with therapeutic potential for the treatment of glioblastomas [abstract]. In: Proceedings of the 103rd Annual Meeting of the Amerian Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR. 2012;():Abstr 1938.

Hawkins ES, Aiken R, Chandler J, Fink KL, Glantz MJ, Grewal J, Gruber ML, Kesari S, Landolfi JC, LaRocca RV, Lesser GJ, Markert J, Mayer TM, O'Rourke D, Peereboom DM, Phuphanich S, Schiff D, Sloan AE, Stea B, Zhu J-J. A randomized, double-blind, controlled phase IIb study of the safety and efficacy of ICT-107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation [abstract]. J Clin Oncol. 2012;30(15 Suppl):TPS2107.

Sams K, Case LD, Lesser GJ, Naughton MJ, Williford SK, Giguere JK, Garino A, Vitolins M, Shaw EG. Comparing three validated methods of patient self-reported fatigue in a prospective randomized clinical trial [abstract]. J Clin Oncol. 2012;30(15 Suppl):Abstr 9108.

Attia A, Rapp SR, Case LD, D'Agostino R, Lesser G, Naughton M, McMullen K, Rosdhal R, Shaw EG. Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. J Neurooncol. 2012;109(2):357-363.

High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of Panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10(5):195-201.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Hematology & Oncology

Clinical Interests

Brain Tumors, Cancer Pain Control, Cancer Symptom Management, Neuro-oncology
Glenn J. Lesser, M.D.

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
CP efforts to include in decisions
CP explanations of prob/condition
CP spoke using clear language
Friendliness/courtesy of CP
Likelihood of recommending CP
Patients' confidence in CP
Time CP spent with patient
Wait time at clinic

Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.




The best people ever.


Had a great nurse.


I have absolute faith and confidence in my provider.HB


My doctors at Wake have always been great! Made hard experiences better!


I would not have stayed with this doctor for 11 years if I was not confident in his care and treatment> Survey a waste of time for me and I will not do any more!


They have always done a great job and have been respectful to us!


*Dr. Glenn Lesser is one of the most outstanding doctors, men, gentlemen - MALE I've ever had the privilege to meet.


*Dr. Lesser is the best!


Everyone was thorough, professional and courteous


My health has improved under *Dr. Lesser's care.


Dr. Lesser is a very good provider ( Physician).


Great experience. Highly recommend Dr. Lesser.


Excellent doctor & staff.


Best experience with *Dr. Lesser - very caring & compassionate doctor.


The best.


*Dr. Lesser is a wonderful doctor.


Very good experience.


very qualified

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.